MGMT and neoplasm: To prospectively clarify the role of MGMT status as a predictive factor, the MGMT NET trial aims to explore the contribution of MGMT gene methylation on tumor tissue in predicting the objective response in patients treated with alkylating agents and to compare treatment with alkylating agents to oxaliplatin in patients with a duodeno-pancreatic, lung or unknown primitive NET (NCT03217097).